Follow us on:
Breaking News
February 20th, 2026
CP Direct: Friday Edition
Breaking News

Johnson & Johnson to Invest Over $1B in Cell Therapy Manufacturing Facility in PA

 
Johnson & Johnson to Invest Over $1B in Cell Therapy Manufacturing Facility in PA

Will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.
Read More >>

Top Headlines

Breaking News

Lonza Strengthens Advanced Synthesis Offering

Increases phase-appropriate support for the discovery and development of ADCs and other bioconjugates.

SPONSOR

Webinar: ADC Payload-Linker CMC Process Development Strategy

Join AsymBio Feb 26 for a CMC roadmap on guidance interpretation, route design, starting materials, stage-based QC and purification process.

Breaking News

MGS Opens New Manufacturing Facility in Richfield, Wisconsin

Will create 300 jobs across engineering, production, automation, quality, and mold maintenance.

Breaking News

PL BioScience Names Summit Pharmaceuticals as Exclusive Japan Distributor

Summit Pharmaceuticals to distribute PL BioScience’s ELAREM Ultimate-FD PLUS and broader ELAREM portfolio for clinical applications.

SPONSOR

[PODCAST] High-Risk Chemistry, Smarter Development: Inside Valsynthese’s CDMO Expertise

R&D Chemist and Project Manager Luca Allievi joins Ben Locwin to discuss nitration, phosgenation, and the power of DoE in sustainable process development.

Rentschler_Webinar_02-26-26_650x250

Breaking News
Collaborations & Alliances

VivaMed, Syngene Collaborate on AI-Powered Validation Infrastructure Expansion

Syngene’s preclinical development capabilities will be called upon to integrate with VivaMed’s AI-derived therapeutic hypotheses.

Features

The Evolution of Biotech and CDMO Partnerships: A 2026 Outlook

Why agility, scalability, and true collaboration are redefining biotech–CDMO relationships.

SPONSOR

Digital PCR: Raising the Bar for Precision in Molecular Testing

How digital PCR is revolutionizing drug development with unmatched sensitivity, accuracy, and regulatory confidence.

Featured Resources

Solution Center SPOTLIGHT

Abzena

Abzena is the leading end-to-end bioconjugate (ADC, AOC, & RDC) & complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development and manufacture of new treatments for patients. Let us help move your program forward faster.

 

Solution Center SPOTLIGHT

Suanfarma CDMO

Suanfarma CDMO provides integrated, end-to-end solutions for development and commercialization services of Intermediates and Drug Substances for Small Molecules. We specialize helping pharmaceutical, biotech and healthcare companies delivering full integrated services that compress timelines to market maximizing success. We have the best know-how and technologies to carry out fermentation, purification, and chemical synthesis processes in our CDMO plants including Regulatory support.